帕妥珠单抗
医学
曲妥珠单抗
肿瘤科
多西紫杉醇
生物仿制药
临床终点
内科学
乳腺癌
佐剂
置信区间
紫杉烷
新辅助治疗
临床试验
随机对照试验
临床研究阶段
危险系数
相对风险
作者
Jin Zhang,Jinhai Zhu,Yaping Yang,Dong Song,Tao Huang,Xiaopeng Ma,莫钦国,Xiaobo Du,Chunwei Xie,Yu Tang Ren,Fan Li,Bo Zhang,Xujuan Wang,Zhaofeng Niu,Hongsheng Li,Peifen Fu,Qingyuan Zhang,Min-Ying Li,Xiaoyu Liu,王启堂
标识
DOI:10.1158/1078-0432.ccr-26-1604
摘要
PURPOSE: This randomized, double-blind phase 3 equivalence study aimed to evaluate the similarity of neoadjuvant pertuzumab biosimilar HLX11 versus reference pertuzumab plus trastuzumab and docetaxel for human epidermal growth factor receptor 2-positive, hormone receptor-negative early-stage or locally advanced breast cancer (BC). PATIENTS AND METHODS: Eligible patients were randomly assigned (1:1) to receive 4 cycles of neoadjuvant HLX11 (HLX11 arm) or European Union-sourced pertuzumab, plus trastuzumab and docetaxel (EU-pertuzumab arm). Patients in the respective arms received adjuvant HLX11 plus trastuzumab or were re-randomized (1:1) to receive HLX11 or EU-pertuzumab plus trastuzumab. The primary endpoint was blinded independent central review (BICR)-assessed total pathological complete response (tpCR) rate. RESULTS: In total, 908 patients were randomized to the HLX11 (n = 454) or EU-pertuzumab arm (n = 454); 192 patients in HLX11 arm received adjuvant HLX11; 200 patients in EU-pertuzumab arm were re-randomized to receive adjuvant HLX11 (n = 100) or EU-pertuzumab (n = 100). BICR-assessed tpCR rate (95% confidence interval [CI]) was 46.3% (41.6%-51.0%) and 45.8% (41.2%-50.5%), respectively. The equivalence criteria were met, with relative risk of tpCR (90% CI) of 1.01 (0.90-1.14) and relative difference (95% CI) of 0.47% (-5.99%-6.92%). No clinically meaningful differences were observed in other efficacy endpoints, safety, pharmacokinetics (PK), or immunogenicity. In the adjuvant phase, switching from EU-pertuzumab to HLX11 led to no notable differences in safety, PK, or immunogenicity. CONCLUSIONS: Compared with EU-pertuzumab, neoadjuvant HLX11 demonstrated a similar tpCR rate and no clinically meaningful differences in other efficacy endpoints, safety, PK, or immunogenicity in BC.
科研通智能强力驱动
Strongly Powered by AbleSci AI